Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization

Fineline Cube Aug 5, 2022

China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...

Company

Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved

Fineline Cube Aug 5, 2022

Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...

Company Drug

Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review

Fineline Cube Aug 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...

Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Company Drug

Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study

Fineline Cube Aug 4, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...

Company Medical Device

Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...

Company Medical Device

Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...

Company Deals

Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues

Fineline Cube Aug 4, 2022

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...

Company Deals

WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld

Fineline Cube Aug 4, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round

Fineline Cube Aug 4, 2022

Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...

Company Drug

Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China

Fineline Cube Aug 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...

Company Drug Legal / IP

ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO

Fineline Cube Aug 4, 2022

China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...

Company

AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines

Fineline Cube Aug 4, 2022

UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...

Company Drug

Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China

Fineline Cube Aug 3, 2022

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...

Company Drug

Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study

Fineline Cube Aug 3, 2022

Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...

Company Drug

Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment

Fineline Cube Aug 3, 2022

Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...

Company Deals

Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing

Fineline Cube Aug 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...

Company Deals

Taibang Biologic Raises $300M in Post-Privatization Financing Round

Fineline Cube Aug 3, 2022

Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...

Company Deals

Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies

Fineline Cube Aug 3, 2022

Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...

Posts pagination

1 … 633 634 635 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.